Should I buy or sell Fusion Pharmaceuticals stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fusion Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FUSN shares. View FUSN analyst ratings or view top-rated stocks .

What is Fusion Pharmaceuticals' stock price target for 2024?

6 analysts have issued twelve-month target prices for Fusion Pharmaceuticals' stock. Their FUSN share price targets range from $10.00 to $13.00. On average, they expect the company's share price to reach $12.20 in the next twelve months. This suggests a possible upside of 112.5% from the stock's current price. View analysts price targets for FUSN or view top-rated stocks among Wall Street analysts .

How have FUSN shares performed in 2023?

Fusion Pharmaceuticals' stock was trading at $3.15 at the beginning of 2023. Since then, FUSN stock has increased by 82.2% and is now trading at $5.74. View the best growth stocks for 2023 here .

Are investors shorting Fusion Pharmaceuticals?

Fusion Pharmaceuticals saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 92,200 shares, a decline of 35.9% from the October 31st total of 143,900 shares. Based on an average daily volume of 180,200 shares, the days-to-cover ratio is currently 0.5 days. View Fusion Pharmaceuticals' Short Interest .

When is Fusion Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our FUSN earnings forecast .

How were Fusion Pharmaceuticals' earnings last quarter?

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) announced its earnings results on Tuesday, November, 7th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.15. The company had revenue of $2.01 million for the quarter, compared to analyst estimates of $0.41 million. Fusion Pharmaceuticals had a negative trailing twelve-month return on equity of 48.42% and a negative net margin of 4,136.55%.

What other stocks do shareholders of Fusion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fusion Pharmaceuticals investors own include Overstock.com (OSTK) , U.S. Xpress Enterprises (USX) , Camping World (CWH) , DocuSign (DOCU) , Pfizer (PFE) , Pure Storage (PSTG) , CrowdStrike (CRWD) , Livongo Health (LVGO) , NVIDIA (NVDA) and OPKO Health (OPK) .

When did Fusion Pharmaceuticals IPO?

(FUSN) raised $126 million in an initial public offering (IPO) on Friday, June 26th 2020. The company issued 8,400,000 shares at $14.00-$16.00 per share. Morgan Stanley, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Fusion Pharmaceuticals' major shareholders?

Fusion Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Federated Hermes Inc. (14.75%), Avidity Partners Management LP (7.98%), FMR LLC (5.77%), Eagle Health Investments LP (0.84%), Forefront Analytics LLC (0.05%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adams Street Partners Llc, John Valliant and Steven Gannon . View institutional ownership trends .

How do I buy shares of Fusion Pharmaceuticals?

Shares of FUSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Fusion Pharmaceuticals Stock Price, News & Analysis (NASDAQ:FUSN)

$5.74

+0.34 (+6.30%)

(As of 12/7/2023 ET)

Compare

Today's Range: $5.27
▼
$5.85
50-Day Range: $2.48
▼
$5.74
52-Week Range: $2.30
▼
$5.85

Volume: 409,629 shs
Average Volume: 182,544 shs
Market Capitalization: $415.61 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.20

Fusion Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 112.5% Upside
$12.20 Price Target
Short Interest: Healthy
0.13% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.92
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.47) to ($1.40) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

152nd out of 960 stocks

Biological Products, Except Diagnostic Industry

16th out of 141 stocks

3.5

Analyst's Opinion

Consensus Rating
Fusion Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.20, Fusion Pharmaceuticals has a forecasted upside of 112.5% from its current price of $5.74.
Amount of Analyst Coverage
Fusion Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.13% of the outstanding shares of Fusion Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Fusion Pharmaceuticals has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Fusion Pharmaceuticals has recently decreased by 35.93%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Fusion Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Fusion Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for FUSN.

3.8

News and Social Media Coverage

News Sentiment
Fusion Pharmaceuticals has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Fusion Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
3 people have searched for FUSN on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
MarketBeat Follows
2 people have added Fusion Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Fusion Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.75% of the stock of Fusion Pharmaceuticals is held by insiders.
Percentage Held by Institutions
72.85% of the stock of Fusion Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Fusion Pharmaceuticals are expected to grow in the coming year, from ($1.47) to ($1.40) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Fusion Pharmaceuticals is -3.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Fusion Pharmaceuticals is -3.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Fusion Pharmaceuticals has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Fusion Pharmaceuticals Stock (NASDAQ:FUSN)

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. Its lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers. The company has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.

FUSN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

FUSN Stock News Headlines

December 1, 2023 | americanbankingnews.com

Fusion Pharmaceuticals Inc. to Post FY2023 Earnings of ($1.40) Per Share, B. Riley Forecasts (NASDAQ:FUSN)

November 27, 2023 | finance.yahoo.com

How Much Upside is Left in Fusion Pharmaceuticals Inc. (FUSN)? Wall Street Analysts Think 162%

December 8, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 16, 2023 | markets.businessinsider.com

BWXT Medical To Assist Fusion In Actinium-225 Production By Providing Access To Generator Technology

November 16, 2023 | financialpost.com

BWXT Medical Expands Collaboration with Fusion Pharmaceuticals Through Strengthened Actinium Supply and Access to Generator Technology

November 9, 2023 | markets.businessinsider.com

Positive Outlook on Fusion Pharmaceuticals: Analysis of Strong Cash Position, Potential First-in-Class Status, and Advancing Clinical Assets

November 8, 2023 | morningstar.com

Fusion Pharmaceuticals Inc Ordinary Shares FUSN

November 8, 2023 | markets.businessinsider.com

Fusion Pharmaceuticals: Promising Clinical Progress and Solid Financial Health Bolster Buy Rating

December 8, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

November 7, 2023 | finance.yahoo.com

Fusion Pharmaceuticals Inc. (FUSN) Reports Q3 Loss, Tops Revenue Estimates

November 7, 2023 | finance.yahoo.com

Fusion Pharmaceuticals Inc (FUSN) Reports Q3 2023 Financial Results and Clinical Program Updates

November 7, 2023 | finance.yahoo.com

Fusion Pharmaceuticals Announces Third Quarter 2023 Financial Results and Clinical Program Updates

October 26, 2023 | markets.businessinsider.com

Fusion Pharmaceuticals: Potential Growth Catalysts and Market Opportunities Justify Buy Rating

October 17, 2023 | finance.yahoo.com

Fusion Pharmaceuticals Inc.'s (NASDAQ:FUSN) high institutional ownership speaks for itself as stock continues to impress, up 13% over last week

October 16, 2023 | finance.yahoo.com

Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors

October 12, 2023 | markets.businessinsider.com

Fusion Pharma Presents Preclinical Data Demonstrating Potent Anti-tumor Activity Of FPI-2068

October 12, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Fusion Pharmaceuticals (FUSN)

October 4, 2023 | msn.com

B. Riley Securities Reiterates Fusion Pharmaceuticals (FUSN) Buy Recommendation

September 30, 2023 | msn.com

Oppenheimer Initiates Coverage of Fusion Pharmaceuticals (FUSN) with Outperform Recommendation

September 5, 2023 | finance.yahoo.com

Fusion Pharmaceuticals to Present at Upcoming September Investor Conferences

August 29, 2023 | msn.com

Raymond James Maintains Fusion Pharmaceuticals (FUSN) Outperform Recommendation

August 14, 2023 | finance.yahoo.com

10 Oversold Penny Stocks To Buy

August 13, 2023 | markets.businessinsider.com

Fusion Pharmaceuticals (FUSN) Gets a Buy from Truist Financial

August 8, 2023 | finance.yahoo.com

Fusion Pharmaceuticals Inc. (FUSN) Reports Q2 Loss, Misses Revenue Estimates

August 8, 2023 | finance.yahoo.com

Fusion Pharmaceuticals Announces Second Quarter 2023 Financial Results and Clinical Program Updates

June 29, 2023 | msn.com

Wedbush Reiterates Fusion Pharmaceuticals (FUSN) Outperform Recommendation

June 29, 2023 | finance.yahoo.com

One Fusion Pharmaceuticals Insider Raised Stake By 370% In Previous Year

See More Headlines

Receive FUSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2023
Today: 12/07/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/21/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:FUSN
CUSIP: N/A
CIK: 1805890
Web: fusionpharma.com
Phone: 289-799-0891
Fax: N/A
Employees: 101
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $12.20
High Stock Price Target: $13.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +112.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.63)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-87,610,000.00
Net Margins: -4,136.55%
Pretax Margin: -4,175.00%
Return on Equity: -48.42%
Return on Assets: -36.27%

Debt

Debt-to-Equity Ratio: 0.18
Current Ratio: 11.63
Quick Ratio: 11.63

Sales & Book Value

Annual Sales: $2.21 million
Price / Sales: 188.23
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.62 per share
Price / Book: 1.59

Miscellaneous

Outstanding Shares: 72,406,000
Free Float: 66,795,000
Market Cap: $415.61 million
Optionable: Not Optionable
Beta: -1.10

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Dr. John F. Valliant Ph.D. (Age 53)
Founder, CEO & Director
Comp: $864.72k
Mr. John J. Crowley CPA (Age 49)
Chief Financial Officer
Comp: $670.1k
Dr. Eric Burak Ph.D. (Age 58)
Chief Technology Officer
Comp: $638.04k
Mr. Mohit Rawat (Age 43)
President & Chief Business Officer
Dr. Christopher Paul Leamon Ph.D. (Age 57)
Chief Scientific Officer
Ms. Amanda Cray
Senior Director of Investor Relations & Corporate Communications
Ms. Maria D. Stahl (Age 52)
Chief Legal Officer
Mr. Eric S. Hoffman Ph.D. (Age 53)
Senior Vice President of Business Development
Dr. Cara Ferreira Ph.D.
Chief of Staff
Dr. Joanne Schindler
Executive Vice President of Medical Director & Clinical Development

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

FUSN Stock Analysis - Frequently Asked Questions

Should I buy or sell Fusion Pharmaceuticals stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fusion Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FUSN shares.
View FUSN analyst ratings or view top-rated stocks.
What is Fusion Pharmaceuticals' stock price target for 2024?: 6 analysts have issued twelve-month target prices for Fusion Pharmaceuticals' stock. Their FUSN share price targets range from $10.00 to $13.00. On average, they expect the company's share price to reach $12.20 in the next twelve months. This suggests a possible upside of 112.5% from the stock's current price.
View analysts price targets for FUSN or view top-rated stocks among Wall Street analysts.
How have FUSN shares performed in 2023?: Fusion Pharmaceuticals' stock was trading at $3.15 at the beginning of 2023. Since then, FUSN stock has increased by 82.2% and is now trading at $5.74.
View the best growth stocks for 2023 here.
Are investors shorting Fusion Pharmaceuticals?: Fusion Pharmaceuticals saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 92,200 shares, a decline of 35.9% from the October 31st total of 143,900 shares. Based on an average daily volume of 180,200 shares, the days-to-cover ratio is currently 0.5 days.
View Fusion Pharmaceuticals' Short Interest.
When is Fusion Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our FUSN earnings forecast.
How were Fusion Pharmaceuticals' earnings last quarter?: Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) announced its earnings results on Tuesday, November, 7th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.15. The company had revenue of $2.01 million for the quarter, compared to analyst estimates of $0.41 million. Fusion Pharmaceuticals had a negative trailing twelve-month return on equity of 48.42% and a negative net margin of 4,136.55%.

What other stocks do shareholders of Fusion Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Fusion Pharmaceuticals investors own include Overstock.com (OSTK), U.S. Xpress Enterprises (USX), Camping World (CWH), DocuSign (DOCU), Pfizer (PFE), Pure Storage (PSTG), CrowdStrike (CRWD), Livongo Health (LVGO), NVIDIA (NVDA) and OPKO Health (OPK).
When did Fusion Pharmaceuticals IPO?: (FUSN) raised $126 million in an initial public offering (IPO) on Friday, June 26th 2020. The company issued 8,400,000 shares at $14.00-$16.00 per share. Morgan Stanley, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who are Fusion Pharmaceuticals' major shareholders?: Fusion Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Federated Hermes Inc. (14.75%), Avidity Partners Management LP (7.98%), FMR LLC (5.77%), Eagle Health Investments LP (0.84%), Forefront Analytics LLC (0.05%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adams Street Partners Llc, John Valliant and Steven Gannon.
View institutional ownership trends.
How do I buy shares of Fusion Pharmaceuticals?: Shares of FUSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:FUSN) was last updated on 12/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Fusion Pharmaceuticals Stock Price, News & Analysis (NASDAQ:FUSN)

Fusion Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Fusion Pharmaceuticals Stock (NASDAQ:FUSN)

FUSN Stock Price History

FUSN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

FUSN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™